ALA — Arovella Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Annual income statement for Arovella Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

	R2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PRESS	ARS	ARS	ARS	ARS
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.576	0.264	0.3	0.436	0.156
Cost of Revenue
Gross Profit	0.375	0.041	0.093	0.232	0.156
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5.5	6.01	8.73	11.6	8.89
Operating Profit	-4.93	-5.75	-8.43	-11.2	-8.74
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4.23	-5.05	-8.62	-10.2	-8.75
Provision for Income Taxes
Net Income After Taxes	-4.23	-5.05	-8.62	-10.2	-8.75
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-9.94	-5.05	-8.62	-10.2	-8.75
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-9.94	-5.05	-8.62	-10.2	-8.75
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.024	-0.012	-0.014	-0.012	-0.009